Last reviewed · How we verify
A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006. JE vaccines give protection by generating a neutralizing antibody response, but both naturally exposed persons and patients with JE also have T cell responses. Whether JE vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to investigate differences in T cell responses between natural exposure, vaccination and disease.
Details
| Lead sponsor | Indian Institute of Science |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 17 |
| Start date | 2012-05 |
| Completion | 2014-03 |
Conditions
- Japanese Encephalitis
- Japanese Encephalitis Vaccine
Interventions
- Live attenuated Japanese encephalitis vaccine SA14-14-2
Primary outcomes
- Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2. — Week 1, week 2, week 4, week 8, 6 months
Interferon gamma (IFNγ) spot forming cells (SFC)/million peripheral blood mononuclear cells (PBMC) at week 2 (peak response)
Countries
India